Across TCGA pan-cancer cohorts, SNORD115-27 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated SNORD115-27 data layer compared with 3 for mass-spec protein.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SNORD115-27 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SNORD115-27 expression acts as an unfavorable survival marker.
LUAD are the cancer types where SNORD115-27 Mutation most reproducibly stratifies survival.